Isofol Medical collaborates closely with Merck & Cie, an affiliate of Merck KGaA, Darmstadt, Germany a leading science and technology company in healthcare, life science and performance materials. The partnership offers many synergies. Isofol Medical has special know-how on the use of reduced folates in anti-cancer therapies and other medical applications. Merck & Cie is the leading cGMP producer of reduced folates, including leucovorin and levoleucovorin, with expertise and know how in process development, formulation and manufacturing of reduced folates such as arfolitixorin (Modufolin®).
Through an exclusive license agreement, Isofol Medical gains access to the unique patented production process and the production capabilities of Merck & Cie for use in clinical trials and the subsequent commercialisation of arfolitixorin (Modufolin®). Through the collaboration, Merck & Cie strengthens its position in developing reduced folates for cancer treatment.
About Merck & Cie
Merck & Cie is the world’s leading supplier of reduced folates such as Metafolin® and Leucovorin. In addition to this, Merck & Cie specializes in the development and production of cGMP grade, highly purified and characterised drug delivery compounds such as cationic lipids, PEGs, PEG-lipids, and phospholipids.
Isofol collaborates closely with Merck’s division in Schaffhausen, Switzerland.
Recipharm is the commercial producer of arfolitixorin (Modufolin®) and has together with Isofol and Merck validated the commercial full scale production method.
Recipharm is a leading European CDMO (Contract Development and Manufacturing Organization) in the pharmaceutical industry based in Sweden, and employing some 1,500 employees.
Offering manufacturing services for pharmaceuticals in various dosage forms, production of clinical trial material and pharmaceutical product development, Recipharm currently manufactures more than 200 different products to both Big Pharma and smaller research- and development companies.
Recipharm’s turnover is approximately SEK 2.1 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany and Spain, it is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq OMX Stockholm.
Sahlgrenska University Hospital (SU) serves as an important clinical development platform forto Isofol Medical. SU, located in Gothenburg, hosts key clinical and medical competence as well as having modern sites for performing Isofol Medical’s clinical trials.
About Sahlgrenska University Hospital
SU provides emergency and basic care for the Gothenburg region. SU also provides highly specialized care for the 1.7 million inhabitants in Western Sweden. SU was founded in 1997 when three hospitals merged; Mölndal Hospital, Sahlgrenska Hospital and Östra Hospital.
The research performed at the research institutions around SU, such as the Sahlgrenska Academy, has resulted in numerous achievements and innovations. Examples include development of the antibiotic PAS against tuberculosis and the blood thinning pharmaceutical Apekumarol. Both of these were developed after the Second World War as a result of research by Jörgen Lehmann. During the 70’s and 80’s, Arvid Carlsson and Björn Folkow successfully contributed to the development of the β-blocker Selokén and L-Dopa for Parkinson’s disease. Arvid Carlsson later won the Nobel Prize in Physiology or Medicine in 2000 for his work on the neurotransmitter Dopamine and his research lead to blockbuster pharmaceuticals. Furthermore, pharmaceuticals such as Losec and Nexium, from Astra Zeneca, have been made possible thanks to key contributions from Lars Olbe at the Sahlgrenska Academy.
Prof Bengt Gustavsson has been active at SU ever since he started his research on the effect of folates on cytotoxics in the late 1970s. The team around him at SU is closely knit, it includes medical scientists, nurses, and laboratory staff that have been involved in his clinical studies and research on the effects of folates on cytotoxics for decades.